MGH Kidney Transplant Clinic
Boston, Massachusetts, 02114, United States
Location status: Recruiting
NCT Number: NCT06751992
The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).
Interested in participating?
Request Info65 year and older
All sexes
Interventional
Phase 4
Boston, Massachusetts, 02114, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Conversion from immediate-release tacrolimus (Prograf) to extended-release tacrolimus (Envarsus XR) as a part of the maintenance immunosuppressive treatment
Other names: Envarsus XR
Continuing immediate-release tacrolimus (Prograf) as a part of the maintenance immunosuppressive treatment
Other names: Prograf
Time frame: 12 month
Neurocognitive functions will be assessed across multiple cognitive domains using the NIH toolbox-Cognitive battery (NIHTB-CB) version 3. The NIHTB-CB version 3 encompasses seven tests to assess attention, executive function, language, memory, and processing speed. The total cognition composite will be derived by averaging normalized scores. The results will be reported in Standard Scores [SS; mean of 100, standard deviation (SD) of 15] adjusting the age of the subject. The investigators will compare the changes in standard score from baseline between the two intervention groups.
Time frame: 12 month
The fluid composite score will be obtained using the NIH toolbox-Cognitive battery (NIHTB-CB) version 3, similarly as described above. The fluid cognition composite will be derived by averaging normalized scores. The results will be reported in Standard Scores [SS; mean of 100, standard deviation (SD) of 15] adjusting the age of the subject. The investigators will compare the changes in standard score from baseline between the two intervention groups.
Time frame: 12 month
The crystallized composite score will be obtained using the NIH toolbox-Cognitive battery (NIHTB-CB) version 3, similarly as described above. The crystallized cognition composite will be derived by averaging normalized scores. The results will be reported in Standard Scores [SS; mean of 100, standard deviation (SD) of 15] adjusting the age of the subject. The investigators will compare the changes in standard score from baseline between the two intervention groups.
Time frame: 12 month
The total composite score will be obtained using the NIH toolbox-Cognitive battery (NIHTB-CB) version 3, similarly as described above. The total cognition composite will be derived by averaging normalized scores. The results will be reported in T scores (mean of 50 and SD of 10) with adjustments for age, gender, education, and race/ethnicity. The investigators will compare the changes in T score from baseline between the two intervention groups.
Time frame: 12 month
The fluid composite score will be obtained using the NIH toolbox-Cognitive battery (NIHTB-CB) version 3, similarly as described above. The fluid cognition composite will be derived by averaging normalized scores. The results will be reported in T scores (mean of 50 and SD of 10) with adjustments for age, gender, education, and race/ethnicity. The investigators will compare the changes in T score from baseline between the two intervention groups.
Time frame: 12 month
The crystallized composite score will be obtained using the NIH toolbox-Cognitive battery (NIHTB-CB) version 3, similarly as described above. The crystallized cognition composite will be derived by averaging normalized scores. The results will be reported in T scores (mean of 50 and SD of 10) with adjustments for age, gender, education, and race/ethnicity. The investigators will compare the changes in T score from baseline between the two intervention groups.
Time frame: 3 month
Same as described above
Time frame: 3 month
Same as described above
Time frame: 3 month
Same as described above
Time frame: 3 month
Same as described above
Time frame: 3 month
Same as described above
Time frame: 3 month
Same as described above
Time frame: 3 month and 12 month
The Standardized Outcome in Nephrology-Life Participation (SONG-LP) questionnaire will evaluate each participant's engagement in significant life domains in correlation with the intervention. This questionnaire assesses life participation in the areas of leisure, family, work, and social activities through four simple questions. The score ranges from 4 to 20, with a higher score indicating greater engagement in life activities. The difference in changes of total score from baseline between the two intervention groups will be obtained.
Time frame: 3 month and 12 month
Quality of Life in Essential Tremor (QUEST) questionnaire will be used to assess tremors subjectively. This questionnaire comprises 30 items contributing to the five dimensions: physical/activities of daily living, psychosocial, communication, hobbies/leisure, and work/finances. The investigators will also obtain self-rated tremor severity in various body parts. The score ranges from 0 to 120, with a higher score indicating a greater impact on their QOL from tremor. The investigators will compare the changes in total score and the score on each scale from baseline between the two intervention groups.
Time frame: 3 month and 12 month
The investigators will assess each participant's sleep quantity using wearable devices. The participants will be instructed to wear the device continuously for 14 days at pre-specified time points during the study period. Sleep quantity will be represented by the total amount of time spent asleep. The difference in changes in sleep quantity from baseline will be compared between the two intervention groups.
Time frame: 3 month and 12 month
The investigators will objectively assess each participant's sleep quality using wearable devices. The participants will be instructed to wear the device continuously for 14 days at pre-specified time points during the study period. Sleep quality will be measured as a percentage of time spent in deep sleep and REM sleep to the total sleep time. A higher percentage indicates a better sleep quality. The changes in sleep quality from baseline will be compared between the two intervention groups.
Time frame: At 3 month and 12 month
The investigators will analyze the differential impact of the intervention in participants aged 75 years and older, compared to those under 75 years old.
Time frame: At 3 month and 12 month
The investigators will perform a subgroup analysis for each outcome based on gender to determine whether the treatment effect varies between males and females.
Time frame: At 3 month and 12 month
The investigators will analyze the differential impact of the intervention in participants with Bachelor's degree holders, compared to those without Bachelor's degree holders.
Time frame: At 3 month and 12 month
The investigators will perform a subgroup analysis for each outcome based on baseline cognitive function to determine whether the treatment effect varies according to baseline cognitive function. Participants with a baseline NIHTB-CB total composite T score ≤ 43 (corresponding to the lower 25th percentile adjusted for age, gender, education, and race/ethnicity) will be separately analyzed to those with a score > 43.
Contact information is provided by the study sponsor or research team.
Massachusetts General Hospital
Other
Neurocognitive Function Changes With Once-Daily Extended-Release Tacrolimus (Envarsus XR) Conversion Compared to Twice-Daily Immediate Release Tacrolimus Maintenance Among Older Kidney Transplant Recipients
Acronym: Neuro-KTR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06881927
Acute Respiratory Failure, Immunosuppressive Agents
Strasbourg, France
View Trial DetailsNCT05938712
Diabetes Mellitus, Diabetes Mellitus, Type 2
Toronto, Ontario, Canada
View Trial DetailsNCT07532694
Kidney Transplant Recipients, Mouth Diseases
Hanoi, Hadong, Vietnam
View Trial DetailsNCT05702398
Kidney Transplant Recipients, Neoplasms
Providence, Rhode Island, United States
View Trial Details